Blue Trust Inc. Acquires 781 Shares of NovoCure Limited (NASDAQ:NVCR)

Blue Trust Inc. increased its position in shares of NovoCure Limited (NASDAQ:NVCR) by 70.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,886 shares of the medical equipment provider’s stock after acquiring an additional 781 shares during the period. Blue Trust Inc.’s holdings in NovoCure were worth $56,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently added to or reduced their stakes in the company. Brooklyn Investment Group bought a new stake in NovoCure in the third quarter valued at approximately $45,000. Venturi Wealth Management LLC lifted its position in NovoCure by 58.5% during the 3rd quarter. Venturi Wealth Management LLC now owns 3,669 shares of the medical equipment provider’s stock valued at $57,000 after acquiring an additional 1,354 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its position in NovoCure by 21.8% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,914 shares of the medical equipment provider’s stock valued at $61,000 after buying an additional 701 shares in the last quarter. Versant Capital Management Inc grew its position in NovoCure by 35.8% during the 4th quarter. Versant Capital Management Inc now owns 3,341 shares of the medical equipment provider’s stock valued at $100,000 after purchasing an additional 880 shares during the last quarter. Finally, Nisa Investment Advisors LLC increased its position in shares of NovoCure by 57.4% during the fourth quarter. Nisa Investment Advisors LLC now owns 4,321 shares of the medical equipment provider’s stock valued at $129,000 after acquiring an additional 1,575 shares in the last quarter. Institutional investors own 84.61% of the company’s stock.

Analyst Ratings Changes

Several analysts recently commented on NVCR shares. HC Wainwright reaffirmed a “buy” rating and issued a $38.00 price objective on shares of NovoCure in a report on Tuesday, January 14th. Piper Sandler lifted their price objective on shares of NovoCure from $28.00 to $42.00 and gave the company an “overweight” rating in a research report on Friday, December 13th. Wedbush reiterated a “neutral” rating and set a $29.00 target price on shares of NovoCure in a research report on Monday, January 13th. Finally, Evercore ISI raised NovoCure from an “in-line” rating to an “outperform” rating and upped their target price for the company from $18.00 to $30.00 in a research note on Monday, December 2nd. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $32.67.

NovoCure Trading Down 1.1 %

Shares of NovoCure stock opened at $21.00 on Wednesday. The firm has a fifty day moving average price of $26.22 and a 200 day moving average price of $21.42. The stock has a market cap of $2.27 billion, a PE ratio of -15.00 and a beta of 0.62. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.49 and a quick ratio of 1.44. NovoCure Limited has a 1 year low of $11.70 and a 1 year high of $34.13.

About NovoCure

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company’s TTFields devices include Optune Gio and Optune Lua.